Category - Developments

Developments

OpSens files 510(k) submission for new guidewire for TAVR procedure

OpSens (TSX:OPS; OTCQX:OPSSF) filed a 510(k) submission with the FDA for regulatory clearance of its new SavvyWire guidewire for transcatheter aortic valve replacement, or TAVR procedures. OpSens previously filed for...

December 13, 2021

Developments

ENDRA, King ’s College Hospital in TAEUS clinical study for NAFLD

ENDRA Life Sciences (NASDAQ:NDRA) is partnering with King’s College Hospital, London (KCH) for a clinical study of ENDRA’s Thermo-Acoustic Enhanced Ultrasound (TAEUS) device for assessing non-alcoholic fatty liver...

December 13, 2021

Developments

Palisade Bio to receive U.S. patent to treat adhesions and postoperative ileus

The United States Patent and Trademark Office (USPTO) has granted a new U.S. patent for Palisade Bio’s (NASDAQ:PALI) lead investigational drug product, LB1148, for use in treating adhesions and postoperative ileus...

December 8, 2021

Developments

Cognetivity, Ketamine One collaborating on depression, PTSD studies

Cognetivity Neurosciences (CSE:CGN; OTCQB:CGNSF; FWB:1UB) entered a collaborative partnership with Ketamine One Capital to study and develop assessments for depression and post-traumatic stress disorder (PTSD). In the...

December 7, 2021

Developments

FSD Pharma unveils video demonstrating disease-modifying effects of Lucid-MS in established animal model of MS

FSD Pharma (NASDAQ, CSE:HUGE; FRA: 0K9) unveiled preclinical data in established animal models of multiple sclerosis, supported by an explanatory video, demonstrating the potentially disease-modifying effects of Lucid...

December 2, 2021

Developments

Sigyn Therapeutics successfully completes study for gram-positive bacterial toxins

Sigyn Therapeutics (OTC: SIGY) reported that preclinical in vitro studies have validated the ability of Sigyn Therapy to deplete the presence of gram-positive bacterial toxins from human blood plasma. Sigyn...

December 1, 2021

Developments

Altamira randomizes first patient in Bentrio trial in seasonal allergic rhinitis

Altamira Therapeutics (NASDAQ:CYTO) randomized the first patient in its NASAR trial for the clinical evaluation of Bentrio (AM-301) in seasonal allergic rhinitis (SAR). Bentrio, a drug-free nasal spray intended for...

December 1, 2021

Developments

Clene presents updated data from RESCUE-ALS Phase 2 study

Clene (NASDAQ:CLNN) presented new data from the RESCUE-ALS Phase 2 study of CNM-Au8, a catalytically active gold nanocrystal suspension, in the treatment of amyotrophic lateral sclerosis (ALS) at the 4th annual ALS ONE...

December 1, 2021

Developments

BeyondSpring receives CRL for plinabulin NDA to prevent CIN

BeyondSpring Pharmaceuticals (NASDAQ:BYSI) received a complete response letter (CRL) from the FDA for its NDA seeking approval of plinabulin in combination with granulocyte colony-stimulating factor (G-CSF) for the...

December 1, 2021

Developments

Palisade Bio to receive European patent for LB1148

Palisade Bio (NASDAQ:PALI) was advised by the European Patent Office that it will receive a patent for its lead investigational drug product, LB1148. The patent will publish on Dec. 22, 2021, and provide protection...

November 30, 2021

Category - Developments

OpSens files 510(k) submission for new guidewire for TAVR procedure

ENDRA, King ’s College Hospital in TAEUS clinical study for NAFLD

Palisade Bio to receive U.S. patent to treat adhesions and postoperative ileus

Cognetivity, Ketamine One collaborating on depression, PTSD studies

FSD Pharma unveils video demonstrating disease-modifying effects of Lucid-MS in established animal model of MS

Sigyn Therapeutics successfully completes study for gram-positive bacterial toxins

Altamira randomizes first patient in Bentrio trial in seasonal allergic rhinitis

Clene presents updated data from RESCUE-ALS Phase 2 study

BeyondSpring receives CRL for plinabulin NDA to prevent CIN

Palisade Bio to receive European patent for LB1148

General

More

Sign up for the BioTuesdays weekly newsletter